Home > Insider Trading > Filing (0001179110-19-008727)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1597264	Blueprint Medicines Corp	BPMC	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1663022	Kate Haviland	C/O Blueprint Medicines Corporation 45 Sidney Street Cambridge MA 02139	Chief Operating Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2019-07-16	11,562	$16.28	17,436	No	4	M	Direct
Common Stock	Disposition	2019-07-16	1,222	$95.60	16,214	No	4	S	Direct
Common Stock	Disposition	2019-07-16	349	$95.03	15,865	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2019-07-16	11,562	$0.00	11,562	$16.28

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
15,647		2026-02-01	No	4	M	Direct

Footnotes

Consists of (i) exercise to acquire 1,571 shares effected pursuant to a trading plan adopted on April 19, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and (ii) a separate cash exercise to acquire 9,991 shares.
The sales reported on this Form 4 were effected pursuant to a trading plan adopted on April 19, 2019 pursuant to Rule 10b5-1 under the Exchange Act.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.29 to $96.16 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.98 to $95.09 per share.
This option was granted on February 1, 2016. This option vested with respect to 25% of the shares underlying the option on January 5, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter.